Imiquimod is an immune response modifier that exerts both antiviral and antitumor activities by activating a pro-inflammatory immune response which is mediated via TLR7-induced IFN-alpha release, which leads to the expression of NF-κB and IFN-gamma and is licensed for the treatment of both skin cancer and genital warts [13]. This evidence concerns the gene TLR7 and anogenital human papillomavirus infection.